| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Department of Pathology, The Gade Institute; 2 Department of Radiology; 3 Centre for Clinical Research, Haukeland University Hospital; 4 Section for Epidemiology and Medical Statistics, Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway; 5 Cancer Registry of Norway, Oslo, Norway; and 6 Program in Cancer Genetics, Departments of Oncology and Human Genetics and Medicine, McGill University, Montreal, Quebec, Canada
Requests for reprints: Lars A. Akslen, Vascular Biology Program (Folkman Lab), Karp Family Research Labs 12.125, Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115-5737. Phone: 617-919-2426; Fax: 617-739-5891. E-mail: lars.akslen{at}childrens.harvard.edu
Interval breast cancer reduce the effectiveness of mammography screening programs. We studied 95 interval cancers, diagnosed during 1996 to 2001 as part of the population-based Norwegian Breast Cancer Screening Program. These cases were matched on size (±2.0 mm) to 95 screen-detected breast cancers, and the tumors were compared by immunohistochemical methods using tissue microarrays. Patients with interval cancers were more likely to be younger [odds ratio (OR), 4.7; P = 0.0001], to have dense breasts (OR, 3.4; P = 0.004), and to have estrogen receptor–negative tumors (OR, 2.6, P = 0.01), and p53 expression was more frequent (OR, 4.0; P = 0.001). Notably, interval cancers were more likely to have a basal epithelial phenotype, in that expression of cytokeratin 5/6 (OR, 2.3; P = 0.04) and P-cadherin (OR, 2.5; P = 0.04) was more frequent in interval cases than in size-matched, screen-detected tumors. In a logistic regression model, p53 expression, age, and breast density were independent predictors of interval cancers. Our data suggest that breast cancers with a basal epithelial phenotype are more likely than nonbasal breast cancers to present between regular mammograms.
This article has been cited by other articles:
|
|
 |
|
  E Korsching, S S Jeffrey, W Meinerz, T Decker, W Boecker, and H Buerger Basal carcinoma of the breast revisited: an old entity with new interpretations J. Clin. Pathol., May 1, 2008; 61(5): 553 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dent, M. Trudeau, K. I. Pritchard, W. M. Hanna, H. K. Kahn, C. A. Sawka, L. A. Lickley, E. Rawlinson, P. Sun, and S. A. Narod Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence Clin. Cancer Res., August 1, 2007; 13(15): 4429 - 4434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Robson and K. Offit Management of an Inherited Predisposition to Breast Cancer N. Engl. J. Med., July 12, 2007; 357(2): 154 - 162. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Li, P. Cherukuri, N. Li, V. Cowling, M. Spinella, M. Cole, A. K. Godwin, W. Wells, and J. DiRenzo Nestin Is Expressed in the Basal/Myoepithelial Layer of the Mammary Gland and Is a Selective Marker of Basal Epithelial Breast Tumors Cancer Res., January 15, 2007; 67(2): 501 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Staalesen, S. Knappskog, R. Chrisanthar, S. H. Nordgard, E. Lokkevik, G. Anker, B. Ostenstad, S. Lundgren, T. Risberg, I. Mjaaland, et al. The Novel p21 Polymorphism p21G251A Is Associated with Locally Advanced Breast Cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6000 - 6004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Collett, G. E. Eide, J. Arnes, I. M. Stefansson, J. Eide, A. Braaten, T. Aas, A. P. Otte, and L. A. Akslen Expression of Enhancer of Zeste Homologue 2 Is Significantly Associated with Increased Tumor Cell Proliferation and Is a Marker of Aggressive Breast Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1168 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Bachmann, O. J. Halvorsen, K. Collett, I. M. Stefansson, O. Straume, S. A. Haukaas, H. B. Salvesen, A. P. Otte, and L. A. Akslen EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast J. Clin. Oncol., January 10, 2006; 24(2): 268 - 273. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
